Nova Mentis Life Science Company Information
|Name||Nova Mentis Life Science Corp|
|Industry||Drug Manufacturers—Specialty & Generic|
|Headquarters||700-838 West Hastings Street |
Vancouver, B.C. Canada. V6C 0A6
Nova Mentis Life Science Corp is an industry leader pioneering in developing treatments centered on psilocybin to treat neuroinflammatory conditions like autism spectrum disorder and other related conditions.
The life science company is determined to build and support a diversified collection of investments featuring companies in the health and wellness sector.
This Canadian-based public company was formerly known as Liberty Leaf Holdings Ltd.
Nova Mentis Subsidiaries
Intending to lead the industry with innovative and comprehensive monitoring, diagnosis, and treatment programs, this biotechnology company has dedicated its efforts towards developing psychedelic-based neuroinflammatory treatment.
Neuroinflammatory conditions have not received the required attention, and as a result, most of the patients suffering from these conditions end up not getting proper treatments.
Pilz biotech seeks to meet these needs using psilocybin, with their initial focus being on Autism Spectrum Disorder.
Nova Mentis biotech
The company’s mission is to create progressive and innovative psychedelic medicine to solve society’s big health issues.
Diabetes has become prevalent in our society, affecting more than 300 million people worldwide. This number is not going down: it keeps rising, which calls for a unique and innovative approach. Nova Mentis is dedicated to finding psychedelic-based solutions through research and development.
Obesity leads to diabetes. These two diseases affect close to a billion people combined, with obesity affecting about 700 million individuals.
The condition also leads to cardiovascular disease, certain types of cancers, and osteoarthritis. Through novel treatments, a solution can be achieved, thus lowering the global burden of health.
Nova Mentis Autism Microbe Study Launched in the U.S
On the 3rd of March 2021, Nova Mentis Launched a study dubbed “Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes.”
The US-based study is designed to find a way to meet patients’ unmet medical needs with ASD (Autism Spectrum Disorder).
The clinical study will help establish the specific group of ASD patients who would benefit from psilocybin and other entheogen-based therapy. Microbiome science is vital in discovering the role of gut biology in brain activity and behavior alterations.
The study will conduct a genetic analysis of fecal matter to assess the microbiomes present in the gut and compare the bacterial characteristics with age-matched neurotypical controls.
This particular research is vital since it covers gut bacteria changes, which majorly contributes to GI disorders’ pathophysiology associated with conditions like anxiety, hypersensitivity, and negative shifts in behavioral symptoms.
The study seeks to recruit 300 participants across the United States: 100+ neurotypical controls, and the rest will be patients with either severe or moderate forms of ASD.